Finch Therapeutics Group's gross profit for the
three
months ended in Jun. 2024 was $0.00 Mil. Finch Therapeutics Group's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Finch Therapeutics Group's Gross Profit
For the Biotechnology subindustry, Finch Therapeutics Group's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Gross Profit distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Finch Therapeutics Group (OTCPK:FNCH) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Finch Therapeutics Group had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage
Finch Therapeutics Group Gross Profit Related Terms
Thank you for viewing the detailed overview of Finch Therapeutics Group's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FNCH has been successfully added to your 